Radiglip-M 50 mg/500 mg Tablet

Ülke: Bangladeş

Dil: İngilizce

Kaynak: DGDA (Directorate General of Drug Administration)

Aktif bileşen:

Metformin Hydrochloride + Sitagliptin

Mevcut itibaren:

Radiant Pharmaceuticals Ltd.

INN (International Adı):

Metformin Hydrochloride + Sitagliptin

Doz:

500 mg + 50 mg

Farmasötik formu:

Tablet

Bilgilendirme broşürü

COMPOSITION:
Radiglip-M
TM 50 mg/500 mg Tablet : Each film coated
tablet contains Sitagliptin 50 mg as Sitagliptin Phosphate
USP & Metformin HCl USP 500 mg.
PHARMACOLOGY:
Radiglip-M
TM
combines two antihyperglycemic agents
with complementary mechanisms of action to improve
glycemic
control
in
patients
with
type
2
diabetes.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor,
and Metformin HCl, a member of the biguanide class.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor,
which is believed to exert its actions in patients with
type 2 diabetes by slowing the inactivation of incretin
hormones. Incretin hormones, including glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide
(GIP),
are
released
by
the
intestine
throughout the day, and levels are increased in response
to a meal. These hormones are rapidly inactivated by the
enzyme, DPP-4. The incretins are part of an endogenous
system involved in the physiologic regulation of glucose
homeostasis. When blood glucose concentrations are
normal or elevated then GLP-1 and GIP increase insulin
synthesis and release from pancreatic beta cells by
intracellular signaling pathways involving cyclic AMP.
GLP-1 also lowers glucagon secretion from pancreatic
alpha
cells,
leading
to
reduced
hepatic
glucose
production. By increasing and prolonging active incretin
levels, Sitagliptin increases insulin release and decreases
glucagon levels in the circulation in a glucose-dependent
manner. The pharmacologic mechanism of action of
Metformin HCl is different from other classes of oral
antihyperglycemic
agents.
Metformin
HCl
decreases
hepatic
glucose
production,
decreases
intestinal
absorption of glucose and increases peripheral glucose
uptake and utilization.
INDICATIONS:
Radiglip-M
TM
is
a
dipeptidyl
peptidase-4
(DPP-4)
inhibitor and biguanide combination product indicated
as an adjunct to diet and exercise to improve glycemic
control in adults with type 2 diabetes mellitus when
treatment with both Sitagliptin and Metformin
HCl
is
appropriate.